Literature DB >> 20016466

Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome.

Jérôme Harambat1, Sonia Fargue, Cécile Acquaviva, Marie-France Gagnadoux, Françoise Janssen, Aurélia Liutkus, Chebl Mourani, Marie-Alice Macher, Daniel Abramowicz, Christophe Legendre, Antoine Durrbach, Michel Tsimaratos, Hubert Nivet, Eric Girardin, Anne-Marie Schott, Marie-Odile Rolland, Pierre Cochat.   

Abstract

We sought to ascertain the long-term outcome and genotype-phenotype correlations available for primary hyperoxaluria type 1 in a large retrospective cohort study. We examined the clinical history of 155 patients (129 families primarily from Western Europe, North Africa, or the Middle East) as well as the enzymatic or genetic diagnosis. The median age at first symptom was 4 years, and at diagnosis 7.7 years, at which time 43% had reached end-stage renal disease. Presentations included: (1) early nephrocalcinosis and infantile renal failure, (2) recurrent urolithiasis and progressive renal failure diagnosed during childhood, (3) late onset with occasional stone passage diagnosed in adulthood, (4) diagnosis occurring on post-transplantation recurrence, and (5) family screening. The cumulative patient survival was 95, 86, and 74% at ages 10, 30, and 50 years, respectively, with the cumulative renal survival of 81, 59, 41, and 10% at ages 10, 20, 30, and 50 years, respectively; 72 patients had undergone a total of 97 transplantations. Among the 136 patients with DNA analysis, the most common mutation was p.Gly170Arg (allelic frequency 21.5%), with a median age at end-stage renal disease of 47 years for homozygotes, 35 years for heterozygotes, and 21 years for other mutations. Our results underscore the severe prognosis of primary hyperoxaluria type 1 and the necessity for early diagnosis and treatment, as well as confirm a better prognosis of the p.Gly170Arg mutation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20016466     DOI: 10.1038/ki.2009.435

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  47 in total

1.  Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria.

Authors:  Katharina Hopp; Andrea G Cogal; Eric J Bergstralh; Barbara M Seide; Julie B Olson; Alicia M Meek; John C Lieske; Dawn S Milliner; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2015-02-02       Impact factor: 10.121

Review 2.  Recent advances in the identification and management of inherited hyperoxalurias.

Authors:  David J Sas; Peter C Harris; Dawn S Milliner
Journal:  Urolithiasis       Date:  2018-12-10       Impact factor: 3.436

3.  Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria.

Authors:  Ellen R Brooks; Bernd Hoppe; Dawn S Milliner; Eduardo Salido; John Rim; Leah M Krevitt; Julie B Olson; Heather E Price; Gulsah Vural; Craig B Langman
Journal:  Am J Nephrol       Date:  2016-05-03       Impact factor: 3.754

4.  End Points for Clinical Trials in Primary Hyperoxaluria.

Authors:  Dawn S Milliner; Tracy L McGregor; Aliza Thompson; Bastian Dehmel; John Knight; Ralf Rosskamp; Melanie Blank; Sixun Yang; Sonia Fargue; Gill Rumsby; Jaap Groothoff; Meaghan Allain; Melissa West; Kim Hollander; W Todd Lowther; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-12       Impact factor: 8.237

5.  A non-resolving skin lesion in hemodialysis patient: Answers.

Authors:  Shimrit Tzvi-Behr; Efrat Ben-Shalom; Rachel Becker-Cohen; Graciela Lijozetzky; Jenny Weinbrand-Goichberg; Yaacov Frishberg; Choni Rinat
Journal:  Pediatr Nephrol       Date:  2018-08-28       Impact factor: 3.714

Review 6.  Primary hyperoxaluria in populations of Pakistan origin: results from a literature review and two major registries.

Authors:  Jamsheer Jehangir Talati; Sally-Anne Hulton; Sander F Garrelfs; Wajahat Aziz; Shoaib Rao; Amanullah Memon; Zafar Nazir; Raziuddin Biyabani; Saqib Qazi; Iqbal Azam; Aysha Habib Khan; Jamil Ahmed; Lena Jafri; Mohammad Zeeshan
Journal:  Urolithiasis       Date:  2017-06-28       Impact factor: 3.436

7.  Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria.

Authors:  Xiaojing Tang; Nikolay V Voskoboev; Stacie L Wannarka; Julie B Olson; Dawn S Milliner; John C Lieske
Journal:  Am J Nephrol       Date:  2014-04-26       Impact factor: 3.754

8.  Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele.

Authors:  Sonia Fargue; Jackie Lewin; Gill Rumsby; Christopher J Danpure
Journal:  J Biol Chem       Date:  2012-12-10       Impact factor: 5.157

Review 9.  Primary hyperoxaluria type 1: practical and ethical issues.

Authors:  Pierre Cochat; Jaap Groothoff
Journal:  Pediatr Nephrol       Date:  2013-03-14       Impact factor: 3.714

10.  Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure.

Authors:  Fang Zhao; Eric J Bergstralh; Ramila A Mehta; Lisa E Vaughan; Julie B Olson; Barbara M Seide; Alicia M Meek; Andrea G Cogal; John C Lieske; Dawn S Milliner
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-10       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.